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Background. Bleeding diathesis after aortic valve operation and ascending aorta replacement
(AV–AA) is managed with fresh-frozen plasma (FFP) and platelet concentrates. The aim was to
compare haemostatic effects of conventional transfusion management and FIBTEM (thrombo-
elastometry test)-guided ﬁbrinogen concentrate administration.
Methods. A blood products transfusion algorithm was developed using retrospective data
from 42 elective patients (Group A). Two units of platelet concentrate were transfused after
cardiopulmonary bypass, followed by 4 u of FFP if bleeding persisted, if platelet count
was  100 10
3 ml
21 when removing the aortic clamp, and vice versa if platelet count was
.100 10
3 ml
21. The trigger for each therapy step was  60 g blood absorbed from the
mediastinal wound area by dry swabs in 5 min. Assignment to two prospective groups was
neither randomized nor blinded; Group B (n=5) was treated according to the algorithm,
Group C (n=10) received ﬁbrinogen concentrate (Haemocomplettan
w P/Riastap, CSL Behring,
Marburg, Germany) before the algorithm-based therapy.
Results. A mean of 5.7 (0.7) g ﬁbrinogen concentrate decreased blood loss to below the
transfusion trigger level in all Group C patients. Group C had reduced transfusion [mean 0.7
(range 0–4) u vs 8.5 (5.3) in Group A and 8.2 (2.3) in Group B] and reduced postoperative
bleeding [366 (199) ml vs 793 (560) in Group A and 716 (219) in Group B].
Conclusions. In this pilot study, FIBTEM-guided ﬁbrinogen concentrate administration was
associated with reduced transfusion requirements and 24 h postoperative bleeding in patients
undergoing AV–AA.
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Complex cardiac surgery is frequently accompanied by
excessive perioperative bleeding because of coagulation
system impairment, inadequate surgical haemostasis, or
both.
1 Bleeding increases the risk of re-exploration, allo-
geneic blood transfusion, or perioperative myocardial
infarction, and consequently, associated morbidity and
mortality.
2 Aortic valve operation and ascending aorta
replacement (AV–AA) typically involves hypothermia,
prolonged cardiopulmonary bypass (CPB), and large graft
anastomoses, and is associated with an increased risk of
intra- and postoperative blood loss and high transfusion
rates.
34Conventional haemostatic therapy consists of
transfusion of allogeneic blood products that include fresh-
frozen plasma (FFP), platelet concentrate, and cryoprecipi-
tate. However, although the use of these products was
developed empirically, their haemostatic efﬁcacy has not
been evaluated thoroughly in the surgical setting.
56
Haemocomplettan
w P (brand name in Europe)/Riastap
(brand name in USA) (CSL Behring, Marburg, Germany)
is a highly puriﬁed, lyophilized, virus-inactivated
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can be rapidly reconstituted without the need for thawing
and cross-matching, which are necessary for FFP and
cryoprecipitate. The administration of ﬁbrinogen concen-
trate was originally reserved for replacement therapy in
congenital ﬁbrinogen deﬁciency, and in the USA, Riastap
is only approved for this indication. In the meantime,
European reports on haemostatic therapy with
Haemocomplettan
w P in acquired perioperative deﬁciency
of ﬁbrinogen have been published.
7–11 Acquired ﬁbrino-
gen deﬁciency occurring during and after CPB is associ-
ated with increased bleeding after cardiac surgery.
12 13
However, the haemostatic efﬁcacy of ﬁbrinogen concen-
trate in correcting such deﬁciency in complex cardiac
surgery has not been investigated to date.
To reduce blood component transfusion in cardiac
surgery, point-of-care methods such as thrombelastogra-
phy/thromboelastometry have been applied in algorithms
supporting bleeding management in relation to blood
clotting quality.
14–16 Thromboelastometry (ROTEM
w;
Pentapharm GmbH, Munich, Germany) assesses the vis-
coelasticity of whole blood. One of the ROTEM
w tests,
the FIBTEM test, provides prompt information on the clot
strength speciﬁcally attributed to ﬁbrin/ﬁbrinogen using
cytochalasin-D-induced inactivation of platelets in vitro.
17
This test may be used to guide the administration of ﬁbri-
nogen concentrate for prompt haemostatic therapy.
9–11
We hypothesized that postoperative haemostasis could
be improved by increasing plasma ﬁbrinogen concen-
trations, since bleeding complications were observed to be
lower in patients with high perioperative ﬁbrinogen con-
centrations.
12 13 The primary aim of this pilot study was to
evaluate whether FIBTEM-guided intraoperative ﬁbrino-
gen repletion was able to reduce the use of allogeneic
blood products and postoperative bleeding in patients
undergoing AV–AA.
Methods
The study protocol was approved by the institutional review
board of the Hannover Medical School, and informed
written consent was obtained from patients enrolled in the
prospective part of the study. The inclusion criterion was
elective AV–AA throughout the study. Exclusion criteria for
both the retrospective and the prospective parts of the study
were: any known congenital or acquired bleeding disorders,
severe liver disease or heparin-induced anticoagulation
effects, despite protamine therapy, age under 18 yr, preg-
nancy or nursing, redo surgery, emergency operation, and
positive anamnesis for intake of platelet aggregation inhibi-
tors within 5 days of surgery.
Transfusion algorithm
Retrospective data from all 42 patients undergoing elective
AV–AA in 2006 selected according to the inclusion and
exclusion criteria were obtained from medical records
(Group A). Patients had been transfused without a standar-
dized transfusion protocol or point-of-care laboratory
testing, and had received on average 4 u of FFP and 2 u of
platelet concentrate during and the ﬁrst 24 h after the oper-
ation. On the basis of these data and on algorithms
described in the literature,
14 15 a two-step blood products
transfusion algorithm for patients undergoing AV–AA was
developed (Fig. 1).
In addition, we developed a method for quantifying med-
iastinal bleeding after the completion of heparin neutraliz-
ation and surgical haemostasis after weaning from CPB. The
method was also applied after each therapy step. The surgi-
cal ﬁeld was thoroughly covered with sterile, dry surgical
swabs of known weight after all blood had been removed
using a suction device. Surgical swabs were carefully
r e m o v e da f t e r5m i na n db l o o dl o s sw a sd e t e r m i n e db y
weighing the swabs and measuring the weight increase.
18
On the basis of preliminary measurements, the cut-off
value chosen for clinically relevant diffuse, microvascular
bleeding was 60 g. If between 60 and 250 g had been
absorbed (i.e. 720–3000 g of blood h
21), two-step transfu-
sion therapy was initiated (Fig. 1). Patients with blood loss
.250 g were surgically re-explored and blood loss
re-evaluated in the same way. The ﬁrst step of haemostatic
therapy was administered based on the platelet count. If
the platelet count measured at the removal of the aortic
clamp was .100 10
3 ml
21, patients were initially trans-
fused with 4 u of FFP; if it was  100 10
3 ml
21, therapy
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Fig 1 Flow chart of transfusion algorithm. FFP, fresh-frozen plasma; PC,
platelet concentrates; PLT, platelet count ( 10
3 ml
21); u, unit.
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Each transfusion was to be completed in 15 min and
followed by blood loss measurement. If blood loss was not
reduced to ,60 g, patients who received FFP in the ﬁrst
therapy step then received 2 u of platelet concentrate, and
those who initially received platelet concentrate were
given 4 u of FFP (Fig. 1). If diffuse, microvascular
bleeding persisted, patients received a further 2 u of FFP
and 1 u of platelet concentrate consecutively. After
successful haemostatic therapy, deﬁned as a 5 min blood
loss ,60 g in subsequent assessments, the thorax was
closed.
Prospective treatment groups
Fifteen patients undergoing AV–AA were prospectively
enrolled into Groups B and C. Five consecutive patients in
Group B received transfusion according to the pre-deﬁned
blood products transfusion algorithm. Patients in Group C
received ﬁbrinogen concentrate before being transfused
according to the transfusion algorithm. Fibrinogen concen-
trate dose was determined based on maximum clot ﬁrm-
ness (MCF) in the FIBTEM test performed at the removal
of the aortic clamp. With the goal of increasing FIBTEM
MCF in Group C to  22 mm, the following formula was
established:
Fibrinogen concentrateðgÞ¼
½22ðmmÞ FIBTEM MCFðmmÞ  bodyweightðkgÞ c
c¼
0:5ðgÞ
1ðmmÞ 70ðkgÞ
Therefore, the dose of ﬁbrinogen concentrate equalled
(22–FIBTEM MCF) body weight/140. According to this
formula, a patient of 70 kg requires a ﬁbrinogen
concentrate dose of  0.5 g to elevate FIBTEM MCF by
 1 mm.
The dose was rounded to a whole number of grams; the
maximum ﬁbrinogen concentrate dose was arbitrarily set
at 6 g. After ﬁbrinogen administration, patients in Group C
received transfusion according to the algorithm applied to
Group B, if bleeding persisted (Fig. 1).
For both Groups B and C, the transfusion of red blood
cells (RBC) was administered to maintain haematocrit
values between 23% and 25% on CPB, reaching 28% after
CPB when the blood from the extracorporeal circulation
system was re-infused into the patient.
The primary endpoint of the study was transfusion of
allogeneic blood products after CPB in the 24 h postopera-
tive period; the secondary endpoint was the 24 h post-
operative blood loss. Postoperative complications were
documented until the patient was discharged.
Intraoperative management
All patients underwent general anaesthesia induced with
etomidate, fentanyl, and cisatracurium. For maintenance of
anaesthesia, sevoﬂurane was titrated to an end-tidal
concentration of 1–2% until aortic cross-clamping on
CPB. For the duration of CPB, propofol was infused and
additional boluses of fentanyl were given every 30 min
during the operation. All patients received 500 ml of
Ringer’s lactate solution and 500 ml of gelatine polysucci-
nate (Gelafundin
w 0.026, Serumwerk, Bernburg, Germany)
at the start of anaesthesia.
After aortic cannulation and administration of heparin
400 IU kg
21 (Heparin-Natrium-25000-ratiopharm
w,
Merckle GmbH, Blaubeuren, Germany), an extracorporeal
circulation system was established, and the ascending
aorta was replaced with an artiﬁcial graft (Hemashield
GoldTM or PlatinTM, Woven Double Velour Vascular
Graft, Boston Scientiﬁc International SA, Boston, MA,
USA). Moderate hypothermia of 328C was used routinely
in all patients. Before CPB, 1 million kallikrein-inhibiting
units (KIU) of aprotinin were administered, with an
additional 1 million KIU in the CPB priming solution.
After the initial anticoagulation, additional doses of
heparin were given to maintain activated clotting time
over 480 s. The system was primed with 1000 ml of
Ringer’s lactate solution, 500 ml of sodium chloride, and
40 ml of 8.4% sodium bicarbonate. After aorta replace-
ment, patients were re-warmed to a bladder temperature of
36.58C and weaned from CPB. Heparin was neutralized
with protamine sulphate (Protamin Valeant, Valeant
Pharmaceuticals GmbH, Eschborn, Germany) immediately
after CPB. After surgery, patients were transferred to the
intensive care unit (ICU).
Haematological evaluations
Blood samples were drawn serially from the radial artery
catheter (20 gauge) into commercially available pre-ﬁlled
collection vials (Sarstedt, Nuembrecht, Germany), which
contained heparin, citrate, or ethylenediamine tetracetic
acid as the anticoagulant. Blood was sampled before oper-
ation (before induction of anaesthesia), at removal of the
aortic clamp, at the end of CPB, after intraoperative hae-
mostatic therapy, and 24 h after the operation.
Activated partial thromboplastin time (aPTT; Kaolin,
Stago Diagnostica, Asnie `res, France), prothrombin time
(PT; Neoplastine
w, Stago Diagnostica), and ﬁbrinogen
concentration (Clauss method: optical read-out) were
determined using the STA-R
w Analyzer (Stago
Diagnostica & Roche, Germany). Platelet count and hae-
matocrit were measured using the Sysmex XE-2100
(Roche Diagnostics, Mannheim, Germany). Platelet counts
were available within 10–15 min of testing.
A four-channel ROTEM
w device (Pentapharm, Munich,
Germany) was used to perform thromboelastometric analyses
of whole blood samples as described previously.
91 01 61 7
ROTEM
w analyses were performed using 300 ml of whole
blood and 20 ml of 0.2 M calcium chloride together with
speciﬁc activators. In the EXTEM test, the activator used
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cytochalasin-D was added to rabbit brain thromboplastin
in order to inhibit the contribution of platelets to the for-
mation of the ﬁbrin clot. The following parameters were
recorded for the ROTEM
w tests: clotting time [CT (s);
time from the start of the test until a clot ﬁrmness of
2 mm is detected] and MCF (mm).
Blood count, coagulation factors, and thromboelastome-
try were measured at the start of the procedure, after CPB,
after coagulation therapy, and 24 h after operation. Only
platelet count and thromboelastometry at the time point of
unclamping the aorta were relevant for the planning of the
coagulation therapy, so no other measures were recorded
at this stage. ROTEM
w results were concealed from the
attending anaesthetists, surgeons, and intensive care phys-
icians. The measurements were performed by a member of
the anaesthesiology department not involved in patient
operation management.
Statistical analysis
The differences between the groups were analysed with
regard to patient characteristics, intraoperative and 24 h
postoperative transfusion of allogeneic blood products, and
24 h postoperative blood loss. The primary endpoint, the
use of allogeneic blood products, was compared between
the retrospective Group A and the prospective ﬁbrinogen
therapy Group C. The secondary endpoint, the 24 h post-
operative blood loss, was compared between the same two
groups. Group B was used to assess whether signiﬁcant
differences in transfusion parameters would be induced by
standardizing the transfusion practice compared with the
retrospective Group A. Because detailed coagulation ana-
lyses were not available in Group A (historical control)
during CPB and at the end of CPB, data obtained from the
prospective conventional therapy (Group B) were com-
pared with those from Group C. On the basis of our pre-
vious experience with ROTEM
w assays, a minimal sample
size of 5 was needed to detect a 30% change in MCF
values with a b-value of .0.8 and an a-value of ,0.05.
Data are presented as mean (SD). Continuous variables
were analysed with a Mann–Whitney U-test; categorical
variables were analysed using the x
2 test. A P-value of
 0.05 was considered to be statistically signiﬁcant.
Results
All patient groups were similar with regard to preoperative
characteristics (Table 1). For the prospective groups (B
and C), the main parameters guiding the initial treatment
step were comparable, namely platelet count at removal of
the aortic cross-clamping (mean 135 10
3 and 137 10
3
ml
21, respectively) and the 5 min blood loss assessment
after weaning from CPB [mean 137 (54) and 133 (55) g,
respectively].
Five patients were recruited to the prospective, blood
products therapy group (B). Mean 5 min blood loss was
84 (12) g after the ﬁrst therapy step. As a result of a defec-
tive FFP bag, one patient only received 3 u of FFP. One
patient had blood loss below 60 g, and therefore no
additional haemostatic therapy was required. Intraoperative
bleeding was successfully managed after the second
therapy step in all patients; the mean 5 min blood loss
decreased to 49 (6) g. The retrospective and the prospec-
tive group treated with allogeneic blood products, Groups
A and B, were comparable regarding bleeding and transfu-
sion parameters, that is, these were not inﬂuenced by the
introduction of the standardized transfusion algorithm. The
patients in these groups were also comparable with regard
to postoperative parameters in the ICU. Regarding stan-
dard laboratory data, preoperative levels of haematocrit
appeared lower in Group B than in Group A, but the
difference was not signiﬁcant (Table 2). Other laboratory
parameters, including platelet count, were comparable at
all times.
The amount of RBC concentrate used on CPB was com-
parable between the groups (Table 3). The 10 patients
recruited to the prospective Group C received a mean dose
of 5.7 (0.7) g ﬁbrinogen concentrate. This effectively
reduced the 5 min blood loss from 133 (55) g after
weaning from CPB to 32 (18) g (,60 g in all patients).
Therefore, according to the transfusion algorithm, no
additional intraoperative administration of FFP or platelet
concentrates was necessary after the end of CPB in this
group. After the operation and during the ﬁrst 24 h in the
ICU, only two patients treated with ﬁbrinogen concentrate
required transfusion [mean 0.7 (range 0–4) u in Group C
vs 8.5 (5.3) and 8.2 (2.3) u in Groups A and B, respect-
ively] (Table 3). Group C had lower 24 h drainage than
the retrospective Group A (Table 3). Intubation time and
Table 1 Characteristics in patients undergoing AV–AA. Data presented as mean (range), mean (SD) or absolute
Group A (retrospective) (n=42) Group B (n=5) Group C (+ﬁbrinogen) (n=10)
Age (yr) 57 (33–89) 61 (47–76) 57 (25–76)
Weight (kg) 84 (14) 94 (8) 90 (20)
Body mass index (kg m
22) 27 (5) 27 (2) 29 (5)
Female (n)1 4 0 2
Coronary heart disease (n)6 1 1
Peripheral vascular disease (n)3 0 2
Cerebrovascular disease (n)2 0 0
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lower in Group C (Table 3).
Standard laboratory analyses showed that preoperative
values were comparable across the groups (Table 1). For
all groups, the coagulation parameters were similarly
affected during CPB, reﬂected by the analysis performed
upon removal of the aortic clamp (Tables 2 and 4).
Analysis performed after weaning from bypass showed no
Table 2 Laboratory parameters in patients undergoing AV–AA. Data presented as mean (SD). aPTT, activated partial thromboplastin time; CPB,
cardiopulmonary bypass; PT, prothrombin time. *P,0.05 Group C vs Group A;
†P,0.05 Group C vs Group B (P,0.05); there were no statistically signiﬁcant
differences between Groups A and B
Laboratory data Group A (n=42) Group B (n=5) Group C (+ﬁbrinogen) (n=10)
Preoperative laboratory parameters
Haematocrit (%) (normal range: 41.5–50.4) 40 (5) 35 (6) 39 (5)
PT (s) (normal range: 11–13.5) 15 (3) 14 (1) 14 (1)
aPTT (s) (normal range: 26–35) 32 (8) 29 (2) 29 (3)
Platelet count (10
3 ml
21) (normal range: 150–450) 202 (63) 204 (46) 196 (33)
Fibrinogen (g litre
21) (normal range: 2.0–4.5) 3.4 (0.6) 3.2 (1.0) 3.3 (1.0)
Removal of aortic clamp
Platelet count (10
3 ml
21) 135 (43) 137 (38)
End of CPB
Haematocrit (%) 29 (2) 29 (4)
PT (s) 19 (1) 20 (2)
aPTT (s) 31 (3) 32 (2)
Platelet count (10
3 ml
21) 103 (26) 104 (23)
Fibrinogen (g litre
21) 2.1 (0.6) 2.2 (0.6)
After coagulation therapy
Haematocrit (%) 28 (3) 25 (3) 28 (4)
†
PT (s) 17 (1) 18 (1) 18 (1)
aPTT (s) 33 (5) 32 (3) 32 (2)
Platelet count (10
3 ml
21) 128 (40) 142 (24) 115 (31)
Fibrinogen (g litre
21) 2.2 (0.4) 2.1 (0.3) 3.6 (0.6)*
,†
First postoperative day
Haematocrit (%) 31 (3) 31 (4) 31 (5)
PT (s) 17 (2) 16 (1) 16 (1)
aPTT (s) 40 (16) 36 (5) 36 (7)
Platelet count (10
3 ml
21) 135 (31) 129 (41) 132 (33)
Fibrinogen (g litre
21) 4.4 (0.6) 4.3 (0.9) 4.4 (0.7)
Table 3 Intra- and postoperative parameters in patients undergoing AV–AA. Data presented as mean (SD) or absolute. CPB, cardiopulmonary bypass; ICU,
intensive care unit; prolonged ventilatory support, ventilatory support .40 h. *P,0.05 Group C vs Group A;
†P,0.05 Group C vs Group B
Parameters Group A (n=42) Group B (n=5) Group C (+ﬁbrinogen) (n=10)
Intraoperative
Aortic clamp time (min) 72 (21) 72 (19) 68 (31)
CPB time (min) 107 (25) 108 (29) 100 (40)
Lowest temperature on CPB (8C) 31.3 (2.2) 31.6 (2.5) 32.8 (2.5)
Red blood cells on CPB (u) 1.1 (1.8) 0.8 (1.3) 0.7 (1.1)
5 min blood loss (ml) after
weaning from CPB N/A 137 (54) 133 (55)
ﬁbrinogen concentrate N/A N/A 32 (18)
ﬁrst therapy step N/A 84 (12) N/A
second therapy step N/A 49 (6) N/A
Postoperative
Patients who did not receive any allogeneic blood after CPB and on ﬁrst day ICU (n)1 0 8 *
,†
ICU time to extubation (h) 13 (12) 12 (5) 9 (5)
ICU time (h) 36 (26) 31 (21) 20 (5)*
,†
Re-exploration for bleeding (n)2 1 0
Postoperative atrial ﬁbrillation (n)6 1 1
Prolonged ventilatory support (n)1 0 0
Major neurological events (n)0 0 0
30 day mortality (n)0 0 0
Postoperative hospitalization (days) 10 (3) 12 (12) 10 (2)
Units transfused/volume drained after CPB and during the ﬁrst 24 h in ICU
Red blood cells (u) 2.4 (2.5) 2.4 (1.1) 0.5 (1.1)*
,†
Fresh-frozen plasma (u) 4.5 (2.1) 4.2 (1.1) 0.2 (0.6)*
,†
Platelet concentrate (u) 1.6 (1.7) 1.6 (0.9) 0.0 (0.0)*
,†
Total blood cell concentrates (u) 8.5 (5.3) 8.2 (2.3) 0.7 (1.5)*
,†
Drainage volume (ml) 793 (560) 716 (219) 366 (199)*
,†
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therapy step, laboratory values showed a higher plasma
concentration of ﬁbrinogen in Group C than in Groups A
and B. However, after 24 h, the ﬁbrinogen plasma concen-
tration was uniformly high in all the groups.
Preoperative ROTEM
w data were comparable between
Groups B and C (Table 4). After therapy, Groups B and C
had similar EXTEM values, but Group C had higher
FIBTEM values (Table 4). However, after 24 h, FIBTEM
and EXTEM values were comparable and within the
normal range in both groups.
Discussion
In this pilot study, haemostatic therapy with ﬁbrinogen
concentrate targeting a high plasma ﬁbrinogen level in
AV–AA patients resulted in a reduction in transfusion of
allogeneic blood products and drainage volume compared
with a historical control group that received conventional
haemostatic therapy.
Before haemostatic therapy, at the end of CPB, coagu-
lation disturbances seen in laboratory tests were compar-
able between the conventional therapy groups (A and B)
and prospective ﬁbrinogen therapy group (Group C). Both
groups had prolonged PT, decreased platelet counts, and
decreased ﬁbrinogen levels compared with baseline. The
administered ﬁbrinogen concentrate [5.7 (0.7) g, represent-
ing  285 ml] restored ﬁbrinogen plasma to baseline levels
without affecting PT and platelet count. Despite the lower
transfusion of RBC, FFP, and platelet concentrate in
Group C, the laboratory data on haematocrit, platelet
count, PT/aPTT, and ﬁbrinogen were comparable among
the three groups at 24 h after surgery.
There are currently ongoing discussions in the literature
concerning the critical level of plasma ﬁbrinogen in
relation to perioperative bleeding.
12 13 19 20 There are
experimental and clinical data describing a protective
effect of high plasma ﬁbrinogen levels. A study by
Velik-Salchner and colleagues
21 reported that the use of
ﬁbrinogen concentrate (250 mg kg
21) was more effective
than platelet concentrate in a porcine hepatic laceration
model in the presence of thrombocytopenia (platelet count
,30 10
3 mm
23). There are  40 000–80 000 glyco-
protein IIb/IIIa receptors on a single, activated platelet,
and the number of these receptors is relatively constant
after CPB.
22 Thrombin generation is decreased after
CPB,
23 but one molecule of thrombin can cleave up to
1680 molecules of ﬁbrinogen.
24 Assuming a simple
enzyme–substrate reaction (Michaelis–Menten equation)
between thrombin and ﬁbrinogen, the Michaelis constant
(Km) value of ﬁbrinogen at 2 g litre
21 (6 mM) represents
half of the maximal reaction rate between thrombin and
ﬁbrinogen.
25 According to the Michaelis–Menten
equation, the targeted ﬁbrinogen level of 3.6 g litre
21 (or
10.7 mM) would nearly maximize the interaction between
ﬁbrinogen and the amount of thrombin available after
CPB, resulting in improved haemostasis. The threshold
level of ﬁbrinogen was also evaluated in obstetric patients
who developed severe post-partum haemorrhage, in which
a ﬁbrinogen level  2 g litre
21 had 100% positive predic-
tive value for bleeding and a level .4 g litre
21 had 79%
negative predictive value for bleeding.
19 Other clinical
studies have shown that a low ﬁbrinogen concentration
better predicts increased bleeding after prolonged CPB.
12 13
In another clinical setting, Heindl and colleagues
11 pre-
viously described the use of ﬁbrinogen (7–8 g) in patients
with major traumatic bleeding refractory to standard
coagulation therapy. Since this ﬁrst report, ﬁbrinogen con-
centrate has been shown to improve haemostasis in
acquired hypoﬁbrinogenaemia associated with cardiac
surgery, liver transplantation, trauma, placental abruption,
dilutional coagulopathy during complex orthopaedic pro-
cedures, and in disseminated intravascular coagulation as a
result of massive blood loss and transfusion.
7–10
Using ﬁbrinogen concentrate as a ﬁrst-line therapy to
correct postoperative bleeding and to reduce the use of
FFP, platelet concentrate, or both seems to be a reasonable
approach as these allogeneic blood products are associated
with various adverse outcomes.
26 27 In addition, as the
average concentrate of ﬁbrinogen in FFP is 2.5 g litre
21,
FFP cannot be used for haemostatic therapy targeting a
plasma ﬁbrinogen level higher than this.
Fibrinogen concentrate administration was guided by
FIBTEM (clot strength in the presence of platelet inhi-
bition) using the empirical target MCF of 22 mm with an
arbitrary limit for the maximal dose set at 6 g ﬁbrinogen
concentrate. This strategy resulted in a mean plasma
Table 4 ROTEM
w values in patients undergoing AV–AA. Data presented as
mean (SD). CPB, cardiopulmonary bypass; EXTEM
w, ROTEM
w test with
extrinsic activation of coagulation; FibTEM
w, ROTEM
w test with extrinsic
activation of coagulation and platelet inhibition with cytochalasin D; CT,
clotting time; MCF, maximal clot ﬁrmness. *P,0.05 Group C vs Group B
ROTEM
w values Group B
(n=5)
Group C
(+ﬁbrinogen) (n=10)
Preoperative
EXTEM
w CT (s) (normal range: 35–80) 71 (7) 69 (7)
EXTEM
w MCF (mm) (normal range:
53–72)
64 (5) 62 (5)
FibTEM
w MCF (mm) (normal range:
9–25)
15 (3) 14 (4)
Removal of the aortic clamp
EXTEM
w CT (s) 104 (32) 132 (73)
EXTEM
w MCF (mm) 58 (6) 56 (6)
FibTEM
w MCF (mm) 12 (2) 11 (3)
End of CPB
EXTEM
w CT (s) 87 (10) 92 (14)
EXTEM
w MCF (mm) 57 (4) 55 (5)
FibTEM
w MCF (mm) 12 (2) 11 (3)
After coagulation therapy
EXTEM
w CT (s) 76 (4) 69 (10)
FibTEM
w MCF (mm) 12 (2) 20 (3)*
First postoperative day
EXTEM
w CT (s) 7 (9) 73 (11)
EXTEM
w MCF (mm) 64 (4) 63 (5)
FibTEM
w MCF (mm) 22 (6) 21 (3)
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790ﬁbrinogen concentration increase (from 2.2 to 3.6 g
litre
21) and an increase in mean FIBTEM MCF from 11
to 20 mm. The decision whether to administer ﬁbrinogen
concentrate had to be made within 10 min after CPB when
diffuse bleeding was diagnosed. The FIBTEM test is rapid
and requires no centrifugation of the sample, a time-
consuming step otherwise necessary in the standard
laboratory-based assessment of ﬁbrinogen concentration.
In contrast to the optical read-out of the Clauss method,
which measures the time to change in turbidity caused by
ﬁbrin formation and estimates ﬁbrinogen plasma concen-
tration from a calibration curve, the FIBTEM provides
information on the mechanical strength of the clot. For all
these reasons, we considered the FIBTEM (ROTEM
w)t o
be the optimal bedside assay to guide the dosage of ﬁbri-
nogen concentrate in this setting.
Because ﬁbrinogen is an acute-phase protein, its level
increases gradually after surgical procedures.
13 Even
though Group C received a mean of 5.7 g of ﬁbrinogen as
haemostatic therapy after weaning from CPB, similar
plasma ﬁbrinogen levels in the three groups and similar
ROTEM
w MCF values in Groups B and C were noted on
postoperative day 1 (Tables 2 and 4). This ﬁnding may be
relevant to the assessment of the safety of administration
of ﬁbrinogen concentrate in this setting. In addition, no
immediate neurological and cardiorespiratory compli-
cations were observed in either group (Table 3).
Other therapeutic options for diffuse bleeding after
weaning from CPB may be considered. In countries where
ﬁbrinogen concentrate is not available, cryoprecipitate may
be used, as it contains a higher concentration of ﬁbrinogen
than FFP.
28 Unlike the ﬁbrinogen concentrate we used
(Haemocomplettan
w P/Riastap, which is pasteurized for
20 h), viral inactivation is not generally applied to cryopre-
cipitate. Therapy with cryoprecipitate therefore carries a
risk of viral transmission equivalent to that of FFP admin-
istration.
29 Recombinant activated factor VII (rFVIIa) has
been increasingly considered an ‘off-label’ rescue haemo-
static agent in cardiac surgery.
30 Although thrombin gener-
ation is decreased after CPB,
23 the balance between
thrombin inhibitors such as antithrombin (also decreased
after prolonged CPB)
23 and thrombin could be disturbed
by adding a drug that generates a ‘thrombin burst’.
A review of the US Food and Drug Administration’s
Adverse Event Reporting System found a total of 431
adverse event reports for rFVIIa from 1999 to 2004,
including 185 thromboembolic events, 90% of which
related to off-label use in patients without haemophilia.
31
This preliminary study has limitations. First, it was not
randomized or blinded and was underpowered to conﬁrm
the efﬁcacy and safety of ﬁbrinogen replenishment in
complex cardiac surgery. The present data were obtained
in a speciﬁc population (AV–AA surgery); therefore, our
ﬁndings may not be appropriate for the management of
every type of post-cardiac surgical bleeding diathesis.
Secondly, the major endpoints in this study only included
the amount of allogeneic blood product use and the 24 h
postoperative blood loss. A longer follow-up of large
numbers of patients would be necessary to conﬁrm the
efﬁcacy of ﬁbrinogen concentrate for haemostatic therapy
and to assess safety parameters such as neurological, car-
diorespiratory, and infectious complications.
In summary, the present data indicate that ﬁbrinogen
concentrate may be effective in reducing both the use of
allogeneic blood products and postoperative bleeding in
aortic surgical patients. To our knowledge, this was the
ﬁrst time that patients with ﬁbrinogen levels within the
normal range (mean 2.2 g litre
21) were substituted with
ﬁbrinogen concentrate to achieve an upper normal range
(mean 3.6 g litre
21). Compared with the allogeneic blood
products, such as FFP, cryoprecipitate, and platelet con-
centrate, ﬁbrinogen concentrate can be potentially time-
saving by precluding the need for cross-matching,
thawing, or both. The FIBTEM MCF was an appropriate
parameter for dosing ﬁbrinogen concentrate in this setting.
A validation study with a prospective, randomized,
placebo-controlled design is currently underway.
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